(Q34105137)

31 July 2017

1 reference

title

Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia (English)

1 reference

31 July 2017

0 references

1 reference

K W Weitzel

1

1 reference

31 July 2017

J M Wickman

series ordinal

2

1 reference

31 July 2017

S G Augustin

series ordinal

3

1 reference

31 July 2017

J G Strom

series ordinal

4

1 reference

31 July 2017

publication date

1 November 2000

1 reference

31 July 2017

published in

Clinical Therapeutics

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

11

1 reference

31 July 2017

page(s)

1254-1267

1 reference

Diagnosis and management of insomnia

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Insomnia and its treatment. Prevalence and correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Drug therapy: The diagnosis and management of insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Management of insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Binding characteristics and interactions of depressant drugs with [35S]t-butylbicyclophosphorothionate, a ligand that binds to the picrotoxinin site.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Zaleplon pharmacokinetics and absolute bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Clinically significant drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

The Benzodiazepine Withdrawal Symptom Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Efficacy of L-846 in patients with insomnia: evaluation by polysomnography.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Psychomotor function and psychoactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects?A review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Chronic use of benzodiazepines and psychomotor and cognitive test performance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

Rapid disappearance of zaleplon from breast milk after oral administration to lactating women.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983024-6

7 January 2021

10.1016/S0149-2918(00)83024-6

Identifiers

DOI

1 reference

31 July 2017

1 reference